# Endothelin receptor antagonists

Drug · id `cardio:endothelin-receptor-antagonists` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Endothelin Receptor Antagonist; Endothelin Antagonists; ERA

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Endothelin receptor antagonists are medicines that block the receptors for endothelin-1, a peptide that acts on blood vessels. MeSH describes the group as compounds and drugs that bind to and block the activation of endothelin receptors. The US labels of Tracleer (bosentan), Letairis (ambrisentan) and Opsumit (macitentan) each call the product an endothelin receptor antagonist indicated for pulmonary arterial hypertension, and each medicine has its own page. This is the class page: what each medicine has been shown to do, and its warnings, sit on its own page.

## Technical summary

Class page. MeSH descriptor D065128 (Endothelin Receptor Antagonists, lastUpdated 2020-05-27) is an exact match; its scope note says these are compounds and drugs that bind to and inhibit or block the activation of endothelin receptors. RxClass lists, for each of bosentan, ambrisentan and macitentan, the established pharmacologic class on US drug labels Endothelin Receptor Antagonist (EPC) and the mechanism-of-action class Endothelin Receptor Antagonists (read 2026-11-18); the three medicines are filed under this page on that evidence. The Letairis label says endothelin-1 acts through two receptor subtypes, ET A and ET B, in vascular smooth muscle and the endothelium. The combination product that pairs macitentan with tadalafil was not read. No trial result, dose or instruction is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The US labels of the member medicines list pulmonary arterial hypertension as the indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Pulmonary arterial hypertension is one type of pulmonary hypertension: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- A separate US product combines an endothelin receptor antagonist, macitentan, with tadalafil, according to its label: Tadalafil (`cardio:tadalafil`)
- Has subtype: Ambrisentan (`cardio:ambrisentan`)
- Has subtype: Bosentan (`cardio:bosentan`)
- Has subtype: Macitentan (`cardio:macitentan`)

## Provenance

Content hash: a83cb07c27e21b500fd5be00ff2d5a6d5c57edf1b393d634c3409c7dff9b0101
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
